Precision Medicine and Oncology Market Access Strategies (Pharmaceuticals)

(Pharmaceuticals) The Saudi precision-medicine sector is experiencing exponential growth, valued at approximately USD 762 million in 2025 and projected to reach USD 1.59 billion by 2033. Despite this trajectory, ultra-high-cost oncology agents and personalized genomic therapies face the highest scrutiny from emerging HTA bodies and risk-averse purchasers such as NUPCO. This course focuses squarely on overcoming the market-access barriers of precision-oncology commercialization. It addresses the analytical challenge of identifying and quantifying microscopic, biomarker-defined patient sub-groups as mandated by SFDA Form A, where the eligible population may be a small fraction of the disease prevalence. Participants are trained to navigate the medical ethics and health economics of national genomic profiling initiatives, balancing access, privacy, and equity considerations unique to genomics. The curriculum provides robust frameworks for establishing performance-based risk-sharing agreements tailored to the volatile, non-linear survival curves characteristic of late-stage oncology therapeutics, where uncertain long-term benefit collides with extreme upfront cost. Through case work drawn from the Saudi oncology landscape, participants learn to build value narratives, quantify sub-group benefit, structure outcome-based deals, and engage purchasers credibly. The outcome is a specialized capability to secure access for transformative but financially challenging precision therapies.